Impacto orçamentário da incorporação do rituximabe para o tratamento de leucemia linfocítica crônica no SUS

Abstract

Objective: This study aims to develop a budget impact analysis (BIA) model related to the incorpo-ration of rituximab in the first-line treatment of chronic lymphocytic leukemia (CLL) in the Unified Health System (SUS). Methods: The preparation of the BIA was carried out in accordance with the methodological recommendations of the Brazilian guidelines, considering the perspective of the SUS, a time horizon of five years, population to be treated, different market share scenarios for rituxi-mab and direct costs involved in the current treatment and treatment proposed, a sensitivity analy-sis was also performed to assess possible future uncertainties. Results: Each year and at the end of the five-year time horizon, the incorporation of rituximab will increase costs, when compared to the SUS reimbursement value for the first-line treatment of CLL. In the scenario of higher market share for rituximab, total costs were lower compared to the scenario of lower market share. Given that the BIA estimate is for future expenses, uncertainties related to the possible increase in the cost of the drug were the factor that promoted the scenario of higher expenses. Conclusions: The projection of costs estimated by the BIA showed lower financial expenses in the scenario of greater diffusion of the drug, which may be correlated with the delay in the progression of the disease when using ritu-ximab and, consequently, fewer patients will require second-line treatment, which has a higher cost.